|
[1]
|
Bingle L, Singleton V, Bingle CD.The putative ovarian tumour marker gene HE4(WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms[J].Oncogene, 2002, 21(17):2768-2773. |
|
[2]
|
赵莹珺, 杨剑锋, 朱景德.人卵巢癌相关基因HE4(WFDC2)的转录调控主要由Sp1与位于-71和-48的Egr-1位点结合所介导[J].肿瘤, 2004, 24(6):517-525. |
|
[3]
|
Kirchhoff C, Habben I, Ivell R, et al.A major human epididymis specific cNDA encodes a protein with sequence homology to extracellular proteinase inhibitors[J].Biol Reprod, 1991, 45(2):350-357. |
|
[4]
|
Schummer M, Ng WV, Bumgarner RE, et al.Comparative hybridization of an array of 21500 ovarian cDNAs for the discovery of genes over expressed in ovarian carcinomas[J].Gene, 1999, 299(1/2):375-385. |
|
[5]
|
Hough CD, Sherman-Baust CA, Pizer ES, et al.Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer[J].Cancer Res, 2000, 60(22):6281-6287. |
|
[6]
|
Hellstrom I, Rayeraft J, Hayden-Ledbetter M, et al.The HE4(WFDC2) Protein is a biomarker for ovarian carcinoma[J].Cancer Res, 2003, 63(13):3695-3700. |
|
[7]
|
连丽娟.林巧稚妇科肿瘤学[M].4版.北京:人民卫生出版社, 2006:182-190. |
|
[8]
|
Montagnanadeng M, Lippi G, Ruzzenente O, et al.The utility of serum human epididymis protein 4(HE4) in patients with a pelvic mass[J].J Clin lab Anal, 2009, 23(5):331-335. |
|
[9]
|
Havrilesky LJ, Whitehead CM, Rubatt JM, et al.Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence[J].Gynecol Oncol, 2008, 110(3):374-382. |
|
[10]
|
Moore RG, Brown AK, Miller MC, et al.The use of multiple novel tumor biomarker for the detection of ovarian carcinoma in patients with a pelvic mass[J].Gynecol Oncol, 2008, 108(2):402-408. |
|
[11]
|
Abdel-Azeez HA, Labib HA, Sharaf SM, et al.HE4 and mesothelin:novel biomarkers of ovarian carcinoma in patients with pelvic masses[J].Asian Pac J Cancer Prev, 2010, 11(1):111-116. |
|
[12]
|
Jacob F, Meier M, Caduff R, et al.No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting[J].Gynecol Oncol, 2011, 121(3):487-491. |
|
[13]
|
Lenhard M, Stieber P, Hertlein L, et al.The diagnostic accuracy of two human epididymis protein 4(HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses[J].Clin Chem Lab Med, 2011, 49(12):2081-2088. |
|
[14]
|
Chang X, Ye X, Dong L, et al.Human epididymis protein 4(HE4) as a serum tumor biomarker in patients with ovarian carcinoma[J].Int J Gynecol Cancer, 2011, 21(5):852-858. |
|
[15]
|
罗兆芹, 赵冰冰, 张玮, 等.血清HE4浓度测定对卵巢恶性肿瘤的诊断价值[J].肿瘤防治研究, 2012, 39(3):312-317. |
|
[16]
|
陈霞, 赵枰, 鲁晓燕.血清中人附睾上皮分泌蛋白4的测定与卵巢上皮性肿瘤患者临床病理特征的关系[J].标记免疫分析与临床, 2010, 17(6):365-367. |
|
[17]
|
陆牡丹, 陈道桢, 赵军, 等.联合检测HE4和CA125在卵巢肿瘤中的表达及其临床意义[J].中国妇幼保健, 2010, 25(25):3623-3625. |
|
[18]
|
郭冰沁, 俞岚, 武世伍, 等.HE4、NF- κBp65和MMP-9在卵巢上皮性肿瘤中的表达及其临床意义[J].中国组织化学与细胞化学杂志, 2011, 20(6):578-583. |
|
[19]
|
卢仁泉, 郭林, 沈烨红.HE4在卵巢癌诊治中的临床应用评价[J].中国癌症杂志, 2010, 20(9):680-685. |
|
[20]
|
李卫兵, 喻海忠, 洪宏.上皮性卵巢癌患者血清HE4水平的改变与临床病理特征的关系[J].放射免疫学杂志, 2010, 23(6):663-665. |
|
[21]
|
刘丽萍, 吴小华, 梁红霞.卵巢癌患者血清SMRP和HE4的表达及其临床意义[J].中国老年杂志, 2011, 31(4):554-557. |
|
[22]
|
Chudecka-Glaz A, Rzepka-Gorska I, Wojciechowska I.Human epididymal protein 4(HE4) is a novel biomarker and a promising prognostic factor in ovarian cancer patients[J].Eur J Gynaecol Oncol, 2012, 33(4):382-390. |
|
[23]
|
Urban N, Thorpe JD, Bergan LA, et al.Potential role of HE4 in multimodal screening for Epithelial Ovarian Cancer[J].J Natl Cancer Inst, 2011, 103(21):1630-1634. |
|
[24]
|
Bandiera E, Romani C, Specchia C, et al.Serum human epididymis protein 4(HE4) and Risk for Ovarian Malignancy Algorithm(ROMA) as new diagnostic and prognostic tools for epithelial ovarian cancer management[J].Cancer Epidemiol Biomarkers Prev, 2011, 20(12):2496-2506. |
|
[25]
|
Molina R, Escudero JM, Auge JM, et al.HE4 a novel tumour marker for ovarian cancer:comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases[J].Tumour Biol, 2011, 32(6):1087-1095. |
|
[26]
|
Kong SY, Han MH, Yoo HJ, et al.Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer[J].Ann Surg Oncol, 2012, 19(5):1707-1712. |
|
[27]
|
Kalapotharakos G, Asciutto C, Henic E, et al.High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer[J].J Ovarian Res, 2012, 5(1):20. |
|
[28]
|
Trudel D, Tetu B, Gregoire J, et al.Human epididymis protein 4(HE4) and ovarian cancer prognosis[J].Gynecol Oncol, 2012, 127(3):511-515. |
|
[29]
|
Drapkin R, Von Horsten HH, Lin Y, et al.Human epididymis protein4(HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J].Cancer Res, 2005, 65(6):2162-2169. |
|
[30]
|
Angioli R, Plotti F, Capriglione S, et al.Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma[J].Gynecol Oncol, 2013, 128(3):579-583. |
|
[31]
|
Anastasi E, Marchei GG, Viggiani V, et al.HE4:a new potential early biomarker for the recurrence of ovarian cancer[J].Tumour Biol, 2010, 31(2):113-119. |
|
[32]
|
Schummer M, Drescher C, Forrest R, et al.Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125[J].Gynecol Oncol, 2012, 125(1):65-69. |
|
[33]
|
宋晓翠, 张文珺, 滕洪涛, 等.血清HE4、CA125联合检测在卵巢癌术后复发诊断中的应用[J].山东医药, 2012, 52(14):75-76. |
|
[34]
|
刘倩, 郭健.HE4和CA125监测老年卵巢癌转归的价值[J].标记免疫分析与临床, 2011, 18(6):374-379. |
|
[35]
|
程洪艳, 刘亚南, 叶雪, 等.血清人附睾分泌蛋白4(HE4)和CA125在卵巢癌患者手术及化疗前后的变化[J].中国妇产科临床杂志, 2011, 12(3):212-215. |
点击查看大图
下载:
